If you’ve been debating starting a weight-loss treatment like tirzepatide or semaglutide, you’re going to want to listen ...

For the twenty-one million American adults experiencing major depressive disorder (MDD) annually, this FDA-approved treatment ...

Joe Faratzis, a 34-year-old who was diagnosed with stage 4 colorectal cancer in 2019, has undergone multiple treatments, ...

Diabetes occurs when the body cannot produce enough insulin to manage a person's blood sugar levels, and doctors treat it ...

Eli Lilly & Co. Inc.'s stock (LLY) rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk's Wegovy in a head-to-head study.

A more precise risk calculation would benefit diabetes screening programs that have become more common in the United States ...

EyePoint Pharmaceuticals has dosed the first patient in the LUCIA Phase 3 trial of Duravyu for wet AMD. The study evaluates ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in ...

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...

Immune checkpoint inhibitors may heighten cardiovascular risks by altering immune interactions in atherosclerotic plaques, ...

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...